Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
EARS Stock Summary
In the News
Auris Medical Announces Launch of New Corporate Website
Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company's recently announced strategic repositioning.
5 Reddit Penny Stocks to Watch That Are Moving Right Now
Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19
Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.
Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.
Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.
EARS Stock Price Increases Over 14% Pre-Market
The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 14% pre-market.
Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs
Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, the assumption of certain selling shareholders' cash outlays, as well as a future share-based payment contingent on reaching a specific development milestone.
EARS Stock Price: Over 9% Increase Pre-Market Explanation
The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.
Auris Medical Holding to Present at LD Micro Invitational XI Conference
Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.
Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo
Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.
EARS Financial details
EARS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
|Revenue per share||31.85||-0.39||0.58||0.1||0.34|
|Net income per share||-289.2||-45.6||-27.27||-26.26||-29.13|
|Operating cash flow per share||-332.87||-57.71||-16.11||-20.64||-9.53|
|Free cash flow per share||-380.44||-78.46||-23.81||-25.67||-11.89|
|Cash per share||135.67||9.52||37.44||1.49||0.02|
|Book value per share||91.81||41.5||55.77||19.18||-9.13|
|Tangible book value per share||2.88||-5.02||25.45||-2.43||-13.41|
|Share holders equity per share||91.81||41.5||55.77||19.18||-9.13|
|Interest debt per share||63.03||0.2||2.19||1.16||7.95|
|Price to sales ratio||5.63||-81.51||79.62||343.87||13.36|
|EV to sales||2.51||-56.79||18.09||337.48||34.02|
|Enterprise value over EBITDA||-0.29||-0.44||-0.6||-1.27||-0.4|
|EV to operating cash flow||-0.24||-0.38||-0.65||-1.58||-1.2|
|EV to free cash flow||-0.21||-0.28||-0.44||-1.27||-0.96|
|Free cash flow yield||-2.12||-2.5||-0.52||-0.77||-2.65|
|Debt to equity||0.39||0||0.03||0.05||-0.76|
|Debt to assets||0.15||0||0.03||0.03||1|
|Net debt to EBITDA||0.36||0.19||2.03||0.02||-0.24|
|Sales general and administrative to revenue||3.37||-70.25||14.87||76.64||11.52|
|Research and developement to revenue||5.28||-59.38||16.41||139.93||64.39|
|Intangibles to total assets||0.36||0.73||0.44||0.76||0.62|
|Capex to operating cash flow||0.14||0.36||0.48||0.24||0.25|
|Capex to revenue||-1.49||53.9||-13.27||-52.06||-7.01|
|Capex to depreciation||-26.01||-97.93||-115.55||-43.56||-18.02|
|Stock based compensation to revenue||0.02||-4.05||2.11||18.88||1.12|
|Return on tangible assets||-1.81||-2.7||-0.7||-3.84||-11.01|
|Tangible asset value||114.41K||-729.48K||7.65M||-1.61M||-12.21M|
|Net current asset value||-162.35K||-816.15K||7.59M||-2.37M||-12.85M|
|Days sales outstanding||92.37||-2.19K||169.16||5.37K||910.68|
|Days payables outstanding||0||0||0||577.4||1.21K|
|Days of inventory on hand||0||0||0||136.71||2.94|
|Capex per share||-47.57||-20.75||-7.7||-5.02||-2.35|
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
|Revenue per share||0||0||0||0||0|
|Net income per share||0||0||0||0||0|
|Operating cash flow per share||0||0||0||0||0|
|Free cash flow per share||0||0||0||0||0|
|Cash per share||0||0||0||0||0|
|Book value per share||0||0||0||0||0|
|Tangible book value per share||0||0||0||0||0|
|Share holders equity per share||0||0||0||0||0|
|Interest debt per share||0||0||0||0||0|
|Price to sales ratio||0||0||0||0||0|
|EV to sales||0||0||0||0||0|
|Enterprise value over EBITDA||0||0||0||0||0|
|EV to operating cash flow||0||0.08||0||0||0|
|EV to free cash flow||0||0.12||0||0||0|
|Free cash flow yield||0||0||0||0||0|
|Debt to equity||0||0.05||0.68||-0.76||-1.9|
|Debt to assets||0||0.03||0.28||1||0.56|
|Net debt to EBITDA||0||0||0||0||0|
|Sales general and administrative to revenue||0||0||0||0||0|
|Research and developement to revenue||0||0||0||0||0|
|Intangibles to total assets||0.61||0.76||0.86||0.62||0.63|
|Capex to operating cash flow||0||-0.35||0||0||0|
|Capex to revenue||0||0||0||0||0|
|Capex to depreciation||0||-37.99||0||0||0|
|Stock based compensation to revenue||0||0||0||0||0|
|Return on tangible assets||0||0||0||0||0|
|Tangible asset value||5.54M||-1.61M||-8.18M||-12.21M||-5.72M|
|Net current asset value||5.5M||-2.37M||-8.88M||-12.85M||-6.3M|
|Days sales outstanding||0||0||0||0||0|
|Days payables outstanding||0||0||0||0||0|
|Days of inventory on hand||0||0||0||0||0|
|Capex per share||0||0||0||0||0|
EARS Frequently Asked Questions
What is Altamira Therapeutics Ltd. stock symbol ?
Altamira Therapeutics Ltd. is a CH stock , located in Zug of Zug and trading under the symbol EARS
What is Altamira Therapeutics Ltd. stock quote today ?
Altamira Therapeutics Ltd. stock price is $3.045 today.
Is Altamira Therapeutics Ltd. stock public?
Yes, Altamira Therapeutics Ltd. is a publicly traded company.